SpringWorks Therapeutics’ (SWTX) Outperform Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX) in a research report sent to investors on Thursday morning,RTT News reports. The firm currently has a $81.00 price target on the stock. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

A number of other research firms have also issued reports on SWTX. Evercore ISI increased their target price on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Guggenheim dropped their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Wednesday, February 12th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and an average price target of $71.50.

SpringWorks Therapeutics Stock Down 2.7 %

SWTX opened at $58.29 on Thursday. The stock has a fifty day moving average of $41.10 and a 200-day moving average of $37.67. The firm has a market capitalization of $4.34 billion, a P/E ratio of -16.75 and a beta of 0.81. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The business had revenue of $61.55 million during the quarter, compared to analysts’ expectations of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, analysts expect that SpringWorks Therapeutics will post -2.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, CEO Saqib Islam sold 10,672 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $59.92, for a total transaction of $639,466.24. Following the transaction, the chief executive officer now directly owns 1,063,953 shares of the company’s stock, valued at $63,752,063.76. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Badreddin Edris sold 20,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the transaction, the chief operating officer now directly owns 209,600 shares in the company, valued at $8,796,912. The trade was a 8.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 313,822 shares of company stock valued at $16,802,876 over the last three months. 7.61% of the stock is currently owned by insiders.

Hedge Funds Weigh In On SpringWorks Therapeutics

Hedge funds have recently bought and sold shares of the business. Huntington National Bank increased its position in SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC grew its position in shares of SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after purchasing an additional 414 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of SpringWorks Therapeutics in the fourth quarter valued at about $45,000. State of Wyoming grew its position in shares of SpringWorks Therapeutics by 39.5% in the fourth quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after purchasing an additional 433 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of SpringWorks Therapeutics in the fourth quarter valued at about $56,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.